Contract Research Organizations Market - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2020f
The global contract research organizations (CROs) market was valued at $41 billion in 2016 and is expected to display a growth around 10% during the forecast period of 2017 to 2024. A CRO is an organization that provide support to the pharmaceutical, biotechnology and medical device companies by offering end-to-end research services on a contract basis. These services include pre-clinical and clinical research, clinical data management (CDM). biostatistics, pharmacovigilance, product development, post-marketing surveillance, drug discovery solutions, site monitoring, central laboratory solutions, etc. The global pharmaceutical sector is witnessing an impressive growth as the global economic recovery continues and demand for advanced medicines increases, predominantly in emerging markets. This growth has provided cash for expenditure in innovation, which has led to very strong pipelines and great FDA approval rates. The growth in R&D activity is expected for some time to come, with many sponsor companies outsourcing research services to CROs due to their limited capacity or to access specialized competencies. For example, most of the pharmaceutical companies outsource their toxicology testing studies to CROs due to the lack of specialized expertise. As a result of above-mentioned factors, the global CRO market expected to grow at a CAGR of around 10% in the coming years.
The global CROs market is segmented based on the type of service, therapeutic area and geographic regions. Based on type of service, the market is segmented into pre-clinical services, phase-I, II, III, IV and other laboratory services. Based on therapeutic area, the market is segmented into CNS, oncology, cardiology, respiratory, infectious diseases and others. Further, based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa (MEA). Amongst these regions, North America dominated the market in 2016 and is expected to retain its dominance till the end of forecast period. This is attributed by the large number of players operating in this region, increasing demand for biosimilars market, stringent regulations by FDA for drug approvals, quality standards in the pharmaceutical industry, and increasing outsourcing activities by pharmaceutical companies.
This research report is designed to analyze and estimate the performance, market demand, and size of the global CROs market across the world. This report includes historical data and forecasts, market size, value chain, product sales, their forecasts, pipeline products and various other key factors that are propelling the growth of this market. The major factors contributing to the growth of this market include strong pharmaceutical demand, increasing complexity and regulatory burden for pharmaceutical companies, to better manage clinical data requirements, and focus on quality. These factors together forced pharmaceutical companies to exploit efficiencies in the drug development and commercialization process by outsourcing to service providers. In reaction, major CROs are increasing their service offerings beyond core clinical services. The most noteworthy near-term growth opportunities for CROs are in the fields of data-driven development strategies, commercialization consulting, and regulatory affairs, since these expertise are scarce in the market. In addition, there has been an increased trend in M&A activities among large CROs to acquire the vendors with these capabilities.
Further, reducing costs, improve time to market, increasing need for novel delivery forms, large number of drugs going off-patent, increasing number of strategic partnerships to identify biologics, government support on research and development activities, desire to improve quality and focus on core marketing activities are expected to drive the market growth in the coming years.
Stringent regulatory requirements for product approvals, insufficient experienced professionals to conduct R&D activities and large number of product recalls from the market owing to the serious complications are some of the challenges, which could hamper the growth of this market. However, introduction of large number of CROs into the market, growing demand for generics, increasing incidence rate of chronic diseases and increasing pressure on pharmaceutical companies to reduce costs will boost the market growth.
The company profile section include detailed analysis of some of the key players such as Agility Clinical, Charles River Laboratories, Covance, DaVita Clinical Research, ICON plc, Inc Research Holdings, Inc., Next Generation Clinical Research, Pra Health Sciences, Inc., Pharmaceutical Product Development, LLC., PAREXEL International Corp., Quintiles Transnational Holdings Inc., and Wuxi Pharmatech Inc.
The global CROs market is segmented based on the type of service, therapeutic area and geographic regions. Based on type of service, the market is segmented into pre-clinical services, phase-I, II, III, IV and other laboratory services. Based on therapeutic area, the market is segmented into CNS, oncology, cardiology, respiratory, infectious diseases and others. Further, based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa (MEA). Amongst these regions, North America dominated the market in 2016 and is expected to retain its dominance till the end of forecast period. This is attributed by the large number of players operating in this region, increasing demand for biosimilars market, stringent regulations by FDA for drug approvals, quality standards in the pharmaceutical industry, and increasing outsourcing activities by pharmaceutical companies.
This research report is designed to analyze and estimate the performance, market demand, and size of the global CROs market across the world. This report includes historical data and forecasts, market size, value chain, product sales, their forecasts, pipeline products and various other key factors that are propelling the growth of this market. The major factors contributing to the growth of this market include strong pharmaceutical demand, increasing complexity and regulatory burden for pharmaceutical companies, to better manage clinical data requirements, and focus on quality. These factors together forced pharmaceutical companies to exploit efficiencies in the drug development and commercialization process by outsourcing to service providers. In reaction, major CROs are increasing their service offerings beyond core clinical services. The most noteworthy near-term growth opportunities for CROs are in the fields of data-driven development strategies, commercialization consulting, and regulatory affairs, since these expertise are scarce in the market. In addition, there has been an increased trend in M&A activities among large CROs to acquire the vendors with these capabilities.
Further, reducing costs, improve time to market, increasing need for novel delivery forms, large number of drugs going off-patent, increasing number of strategic partnerships to identify biologics, government support on research and development activities, desire to improve quality and focus on core marketing activities are expected to drive the market growth in the coming years.
Stringent regulatory requirements for product approvals, insufficient experienced professionals to conduct R&D activities and large number of product recalls from the market owing to the serious complications are some of the challenges, which could hamper the growth of this market. However, introduction of large number of CROs into the market, growing demand for generics, increasing incidence rate of chronic diseases and increasing pressure on pharmaceutical companies to reduce costs will boost the market growth.
The company profile section include detailed analysis of some of the key players such as Agility Clinical, Charles River Laboratories, Covance, DaVita Clinical Research, ICON plc, Inc Research Holdings, Inc., Next Generation Clinical Research, Pra Health Sciences, Inc., Pharmaceutical Product Development, LLC., PAREXEL International Corp., Quintiles Transnational Holdings Inc., and Wuxi Pharmatech Inc.
1.1 Scope of the Report
1.1.1 Report Description
1.1.2 Research Methodology
1.1.3 List of Abbreviations
1.1.4 Market Segmentation
1.2 Executive Summary
1.3 Qualitative Analysis
1.3.1 Drug Discovery and Development Process
1.3.2 Market Overview
1.3.2.1 Drivers
1.3.2.2 Restraints
1.3.3 Value Chain Analysis
1.3.4 Porters Five Forces Analysis
1.3.5 Key M&A Trends and Strategic Partnerships
1.3.6 Competitive Matrix of the Key Companies
1.4 Global Contract Research Organizations Market, by Type of Service
1.4.1 Drug Discovery and Pre-clinical Services
1.4.2 Phase I
1.4.3 Phase - II
1.4.4 Phase - III
1.4.5 Phase – IV
1.4.6 Others (Laboratory Services, etc.)
1.5 Global Contract Research Organizations Market, by Therapeutic Area
1.5.1 Central Nervous System
1.5.2 Cardiac
1.5.3 Oncology
1.5.4 Infectious Diseases
1.5.5 Others
1.6 Contract Research Organizations Market, by Geography
1.6.1 North America
1.6.2 Europe
1.6.3 APAC
1.6.4 Rest of the World
1.7 Company Profiles
1.7.1 Quintiles Transnational Holdings, Inc.
1.7.2 PAREXEL International Corp.
1.7.3 Covance Inc.
1.7.4 PRA Health Sciences
1.7.5 PPDI
1.1.1 Report Description
1.1.2 Research Methodology
1.1.3 List of Abbreviations
1.1.4 Market Segmentation
1.2 Executive Summary
1.3 Qualitative Analysis
1.3.1 Drug Discovery and Development Process
1.3.2 Market Overview
1.3.2.1 Drivers
1.3.2.2 Restraints
1.3.3 Value Chain Analysis
1.3.4 Porters Five Forces Analysis
1.3.5 Key M&A Trends and Strategic Partnerships
1.3.6 Competitive Matrix of the Key Companies
1.4 Global Contract Research Organizations Market, by Type of Service
1.4.1 Drug Discovery and Pre-clinical Services
1.4.2 Phase I
1.4.3 Phase - II
1.4.4 Phase - III
1.4.5 Phase – IV
1.4.6 Others (Laboratory Services, etc.)
1.5 Global Contract Research Organizations Market, by Therapeutic Area
1.5.1 Central Nervous System
1.5.2 Cardiac
1.5.3 Oncology
1.5.4 Infectious Diseases
1.5.5 Others
1.6 Contract Research Organizations Market, by Geography
1.6.1 North America
1.6.2 Europe
1.6.3 APAC
1.6.4 Rest of the World
1.7 Company Profiles
1.7.1 Quintiles Transnational Holdings, Inc.
1.7.2 PAREXEL International Corp.
1.7.3 Covance Inc.
1.7.4 PRA Health Sciences
1.7.5 PPDI
LIST OF FIGURES
FIG. 1 Global CRO Market: Market Segmentation
FIG. 2 Value Chain Analysis: Global CRO Industry
FIG. 3 Competitive Analysis: Global CRO Market, 2014 (%)
FIG. 4 List Contract Research Organizations by Market Segment and Service Offerings, 2014
FIG. 5 Global Contract Research Organizations Market, 2012 - 2020f (USD Billion)
FIG. 6 Global Drug Discovery Services Outsourcing Market, 2012 - 2020f (USD Billion)
FIG. 7 Global Contract Pre-clinical Studies Outsourcing Market, 2012 - 2020f (USD Billion)
FIG. 8 Global Contract Early Phase I-IIa Services Outsourcing Market, 2012 - 2020f (USD Billion)
FIG. 9 Global Contract Phase IIa-III Services Outsourcing Market, 2012 - 2020f (USD Billion)
FIG. 10 Global Contract Phase IIIb-IV Services Outsourcing Market, 2012 - 2020f (USD Billion)
FIG. 11 Global Contract Research Outsourcing Market for Other Services, 2012 - 2020f (USD Billion)
FIG. 12 Global Contract Research Organizations Market, by Therapeutic Areas, 2014 (% Share)
FIG. 13 North America Contract Research Organizations Market, 2012 - 2020f (USD Billion)
FIG. 14 Europe Contract Research Organizations Market, 2012 - 2020f (USD Billion)
FIG. 15 Asia-Pacific Contract Research Organizations Market, 2012 - 2020f (USD Billion)
FIG. 16 Rest of the World Contract Research Organizations Market, 2012 - 2020f (USD Billion)
FIG. 1 Global CRO Market: Market Segmentation
FIG. 2 Value Chain Analysis: Global CRO Industry
FIG. 3 Competitive Analysis: Global CRO Market, 2014 (%)
FIG. 4 List Contract Research Organizations by Market Segment and Service Offerings, 2014
FIG. 5 Global Contract Research Organizations Market, 2012 - 2020f (USD Billion)
FIG. 6 Global Drug Discovery Services Outsourcing Market, 2012 - 2020f (USD Billion)
FIG. 7 Global Contract Pre-clinical Studies Outsourcing Market, 2012 - 2020f (USD Billion)
FIG. 8 Global Contract Early Phase I-IIa Services Outsourcing Market, 2012 - 2020f (USD Billion)
FIG. 9 Global Contract Phase IIa-III Services Outsourcing Market, 2012 - 2020f (USD Billion)
FIG. 10 Global Contract Phase IIIb-IV Services Outsourcing Market, 2012 - 2020f (USD Billion)
FIG. 11 Global Contract Research Outsourcing Market for Other Services, 2012 - 2020f (USD Billion)
FIG. 12 Global Contract Research Organizations Market, by Therapeutic Areas, 2014 (% Share)
FIG. 13 North America Contract Research Organizations Market, 2012 - 2020f (USD Billion)
FIG. 14 Europe Contract Research Organizations Market, 2012 - 2020f (USD Billion)
FIG. 15 Asia-Pacific Contract Research Organizations Market, 2012 - 2020f (USD Billion)
FIG. 16 Rest of the World Contract Research Organizations Market, 2012 - 2020f (USD Billion)
LIST OF TABLES
TABLE 1 Global Contract Research Organizations (CRO) Market – Market Snapshot
TABLE 2 R&D Spending per New Drug, by Company
TABLE 3 Total Number of Drugs Going Off-patent
TABLE 4 Some of the key strategic alliances between biopharmaceutical companies and CROs
TABLE 5 Key M&A deals in CRO industry
TABLE 6 Global CRO Market, Type of Services, 2012 – 2020f (USD Billion)
TABLE 1 Global Contract Research Organizations (CRO) Market – Market Snapshot
TABLE 2 R&D Spending per New Drug, by Company
TABLE 3 Total Number of Drugs Going Off-patent
TABLE 4 Some of the key strategic alliances between biopharmaceutical companies and CROs
TABLE 5 Key M&A deals in CRO industry
TABLE 6 Global CRO Market, Type of Services, 2012 – 2020f (USD Billion)
